<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067129</url>
  </required_header>
  <id_info>
    <org_study_id>M16-123</org_study_id>
    <secondary_id>2016-004102-34</secondary_id>
    <nct_id>NCT03067129</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label study to assess the pharmacokinetics (PK), safety, and efficacy of glecaprevir
      (GLE)/pibrentasvir (PIB) in pediatric participants divided into 4 age groups: 3 to &lt; 6, 6 to
      &lt; 9, 9 to &lt; 12, and 12 to &lt; 18 years of age. Within each age group, some participants will
      be enrolled for intensive pharmacokinetics (IPK) to characterize the PK of a particular age
      group and the remainder of participants will be enrolled for the evaluation of safety and
      efficacy of each age group. Intensive PK sampling is designed to allow for dose adjustment,
      based on available PK and clinical data to achieve therapeutic exposures that have been safe
      and efficacious in adults.

      Part 1 of the study will enroll participants into Cohort 1; Cohort 1 will include
      participants who are in 12 to &lt; 18 years of age who can swallow the adult formulation of
      GLE/PIB. Part 2 of the study will enroll participants in the remaining age groups into
      Cohorts 2, 3, and 4; participants in these cohorts will receive the pediatric formulation of
      GLE/PIB. All participants will receive GLE/PIB for 8, 12, or 16 weeks depending on their
      hepatitis C virus (HCV) genotype, cirrhosis, and prior treatment experience status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of Glecaprevir (GLE)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Pibrentasvir (PIB)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of GLE after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of PIB</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of PIB after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of GLE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Clearance is defined the volume of plasma cleared of the drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of PIB</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Clearance is defined the volume of plasma cleared of the drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Post-treatment relapse is defined as confirmed HCV RNA greater than or equal to the LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA less than LLOQ at the end of treatment; excluding participants who have been shown to be re-infected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experience on-treatment virologic failure (i.e., breakthrough or fail to suppress)</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Virologic failure defined as confirmed increase of greater than 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA less than LLOQ during treatment, or HCV RNA greater than or equal to LLOQ at the end of treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with new HCV infection at any time up to the last study visit</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Participants with new HCV infection at any time up to the last study visit.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB subjects 12 to &lt; 18yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Adult formulation Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8, 12, or 16 weeks depending on their hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB subjects 9 to &lt; 12yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB subjects 6 to &lt; 9yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB subjects 3 to &lt; 6yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet (100 mg/40 mg)</description>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB subjects 12 to &lt; 18yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Oral pediatric formulation</description>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB subjects 9 to &lt; 12yrs</arm_group_label>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB subjects 6 to &lt; 9yrs</arm_group_label>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB subjects 3 to &lt; 6yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis C virus (HCV) infection demonstrated by positive anti-HCV antibody (Ab) and
             HCV Ribonucleic acid (RNA) greater than or equal to 1000 IU/ mL.

          -  Subject must have a weight consistent with a recommended weight range for their age
             at the time of screening.

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding.

          -  Positive test result for Hepatitis B surface antigen (HbsAg) or positive test result
             for HBV DNA.

          -  Participants with other known liver diseases.

          -  Decompensated cirrhosis defined as: presence of ascites, history of variceal
             bleeding, lab values consistent with Child's class B or C cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ucsf /Id# 158002</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB /ID# 158008</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital /ID# 157988</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center /ID# 157997</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine /ID# 157991</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia (CHOP) /ID# 158003</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh, Pennsylvania /ID# 158004</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Jorge Children Hospital /ID# 160850</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>February 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Compensated (Child-Pugh A) cirrhosis</keyword>
  <keyword>Treatment na√Øve</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>Ribavirin (RBV)</keyword>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <keyword>Treatment experienced</keyword>
  <keyword>Interferon (IFN)</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Non-cirrhotic cirrhosis</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>Pibrentasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
